Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CohBar, Inc.CWBR · Entity 124935 | Director | April 26, 2021 | April 28, 2021 |
| MIMEDX GROUP, INC.MDXG · Entity 5271 | Director | June 13, 2023 | June 15, 2023 |
| Revance Therapeutics, Inc.RVNC · Entity 83521 | Director | May 14, 2020 | May 15, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CohBar, Inc.
Report date April 26, 2021 · Filed April 28, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.38 · Expires 2031-04-26 | Direct | 200,000 |
Reported balance
After 2021-04-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-04-26 · Grant · Acquired 200,000 · Balance 200,000 F1: Shares subject to the option shall vest over 48 successive equal installments (rounded down to the nearest whole share, except for the last vesting installment) beginning April 26, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares subject to the option shall vest over 48 successive equal installments (rounded down to the nearest whole share, except for the last vesting installment) beginning April 26, 2021.
MIMEDX GROUP, INC.
Report date June 13, 2023 · Filed June 15, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 117,024 |
Reported balance
After 2023-06-13 transaction · row 1
1 source rowRow 1 · 2023-06-13 · Grant · Acquired 35,354 · Balance 117,024 F1: Represents annual restricted stock unit grant to non-employee directors. Grant is exempt under Rule 16b-3. The award vests upon the earlier of 12 months or the next annual meeting of shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents annual restricted stock unit grant to non-employee directors. Grant is exempt under Rule 16b-3. The award vests upon the earlier of 12 months or the next annual meeting of shareholders.
Revance Therapeutics, Inc.
Report date May 14, 2020 · Filed May 15, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 16,500 |
Reported balance
After 2020-05-14 transaction · row 1
1 source rowRow 1 · 2020-05-14 · Grant · Acquired 6,000 · Balance 16,500 F1: Represents an annual restricted stock award (the "RSA") granted pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the "Compensation Policy"). The shares underlying the RSA shall vest on May 14, 2021, the one year anniversary from the grant date, subject to Dr. Gardner's Continuous Service (as defined the Issuer's 2014 Equity Incentive Plan (the "Plan")) through such vesting date. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.40 · Expires 2030-05-13 | Direct | 12,000 |
Reported balance
After 2020-05-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-05-14 · Grant · Acquired 12,000 · Balance 12,000 F2: The shares subject to the stock option shall vest on May 14, 2021, the one year anniversary from the grant date, subject to Dr. Gardner's Continuous Service (as defined in the Plan) through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an annual restricted stock award (the "RSA") granted pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the "Compensation Policy"). The shares underlying the RSA shall vest on May 14, 2021, the one year anniversary from the grant date, subject to Dr. Gardner's Continuous Service (as defined the Issuer's 2014 Equity Incentive Plan (the "Plan")) through such vesting date.
F2: The shares subject to the stock option shall vest on May 14, 2021, the one year anniversary from the grant date, subject to Dr. Gardner's Continuous Service (as defined in the Plan) through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Corium International, Inc.
Report date November 27, 2018 · Filed November 28, 2018
Section 16 reporting ended · disclosed 2018-11-28. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-11-27 transaction · row 1
1 source rowRow 1 · 2018-11-27 · Disposition to issuer · Disposed 34,203 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR"). |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.14 · Expires 2024-01-25 | Direct | 0 |
Reported balance
After 2018-11-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-11-27 · Disposition to issuer · Disposed 7,920 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR"). F2: Pursuant to the Merger Agreement, at the effective time of the Merger, each option to purchase Shares that was vested and outstanding was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (x) the number of vested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option, plus (ii) one CVR for each Share issuable under such option. This option is fully vested. |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.79 · Expires 2024-12-03 | Direct | 0 |
Reported balance
After 2018-11-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-11-27 · Disposition to issuer · Disposed 12,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR"). F2: Pursuant to the Merger Agreement, at the effective time of the Merger, each option to purchase Shares that was vested and outstanding was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (x) the number of vested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option, plus (ii) one CVR for each Share issuable under such option. This option is fully vested. |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.19 · Expires 2025-12-17 | Direct | 0 |
Reported balance
After 2018-11-27 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-11-27 · Disposition to issuer · Disposed 12,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR"). F2: Pursuant to the Merger Agreement, at the effective time of the Merger, each option to purchase Shares that was vested and outstanding was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (x) the number of vested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option, plus (ii) one CVR for each Share issuable under such option. This option is fully vested. |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.59 · Expires 2026-12-21 | Direct | 0 |
Reported balance
After 2018-11-27 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-11-27 · Disposition to issuer · Disposed 15,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR"). F2: Pursuant to the Merger Agreement, at the effective time of the Merger, each option to purchase Shares that was vested and outstanding was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (x) the number of vested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option, plus (ii) one CVR for each Share issuable under such option. This option is fully vested. |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.59 · Expires 2027-11-30 | Direct | 0 |
Reported balance
After 2018-11-27 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2018-11-27 · Disposition to issuer · Disposed 15,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR"). F2: Pursuant to the Merger Agreement, at the effective time of the Merger, each option to purchase Shares that was vested and outstanding was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (x) the number of vested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option, plus (ii) one CVR for each Share issuable under such option. This option is fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR").
F2: Pursuant to the Merger Agreement, at the effective time of the Merger, each option to purchase Shares that was vested and outstanding was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (x) the number of vested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option, plus (ii) one CVR for each Share issuable under such option. This option is fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 13, 2023 Filed Jun 15, 2023 22:14 UTC | MIMEDX GROUP, INC. MDXG · Entity 5271 | GrantCommon Stock | 35,354 | $4.95 | $175,002.30 |
DisclosureSEC source: 0001376339-23-000040 · wk-form4_1686867247.xml · nonDerivative · entry 1 GARDNER PHYLLIS · CIK 0001238646 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,024 F1 · shares: Represents annual restricted stock unit grant to non-employee directors. Grant is exempt under Rule 16b-3. The award vests upon the earlier of 12 months or the next annual meeting of shareholders. Read SEC document |
| June 07, 2022 Filed Jun 13, 2022 22:32 UTC | MIMEDX GROUP, INC. MDXG · Entity 5271 | GrantCommon Stock | 44,191 | $3.96 | $174,996.36 |
DisclosureSEC source: 0001376339-22-000091 · wf-form4_165515952512983.xml · nonDerivative · entry 1 GARDNER PHYLLIS · CIK 0001238646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,670 F1 · shares: Represents annual restricted stock grant to non-employee directors. Grant is exempt under Rule 16b-3. The award vests upon the earlier of 12 months or the next annual meeting of shareholders. Read SEC document |
| May 27, 2021 Filed May 28, 2021 18:26 UTC | MIMEDX GROUP, INC. MDXG · Entity 5271 | GrantCommon Stock | 17,056 | $10.26 | $174,994.56 |
DisclosureSEC source: 0001376339-21-000075 · wf-form4_162222636414395.xml · nonDerivative · entry 1 GARDNER PHYLLIS · CIK 0001238646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,479 F1 · kind: Represents annual restricted stock grant to non-employee directors. Grant is exempt under Rule 16b-3. The award vests upon the earlier of 12 months or the next annual meeting of shareholders. Read SEC document |
| April 28, 2021 Filed Apr 29, 2021 20:30 UTC | MIMEDX GROUP, INC. MDXG · Entity 5271 | GrantCommon Stock | 4,084 | $10.71 | $43,739.64 |
DisclosureSEC source: 0001376339-21-000034 · wf-form4_161972821997477.xml · nonDerivative · entry 2 GARDNER PHYLLIS · CIK 0001238646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,423 F2 · kind: Grant of restricted stock units which vest in full on the first anniversary date of the grant. Read SEC document |
| April 28, 2021 Filed Apr 29, 2021 20:30 UTC | MIMEDX GROUP, INC. MDXG · Entity 5271 | GrantCommon Stock | 16,339 | $10.71 | $174,990.69 |
DisclosureSEC source: 0001376339-21-000034 · wf-form4_161972821997477.xml · nonDerivative · entry 1 GARDNER PHYLLIS · CIK 0001238646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,339 F1 · kind: Grant of restricted stock units which vest in equal parts over three years from the date of the grant. Read SEC document |
| April 26, 2021 Filed Apr 28, 2021 16:07 UTC | CohBar, Inc. CWBR · Entity 124935 | GrantStock Option (Right to buy) · Derivative | 200,000 | $0.00 Strike: $1.38 | $0.00 |
DisclosureSEC source: 0001213900-21-023261 · ownership.xml · derivative · entry 1 GARDNER PHYLLIS · CIK 0001238646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2031-04-26 F1 · derivative.exercise_date: Shares subject to the option shall vest over 48 successive equal installments (rounded down to the nearest whole share, except for the last vesting installment) beginning April 26, 2021. Read SEC document |
| May 14, 2020 Filed May 15, 2020 18:39 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantStock Option (Right to buy) · Derivative | 12,000 | $0.00 Strike: $19.40 | $0.00 |
DisclosureSEC source: 0001479290-20-000067 · wf-form4_158958237463980.xml · derivative · entry 2 GARDNER PHYLLIS · CIK 0001238646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2030-05-13 F2 · derivative.exercise_date: The shares subject to the stock option shall vest on May 14, 2021, the one year anniversary from the grant date, subject to Dr. Gardner's Continuous Service (as defined in the Plan) through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy. Read SEC document |
| May 14, 2020 Filed May 15, 2020 18:39 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001479290-20-000067 · wf-form4_158958237463980.xml · nonDerivative · entry 1 GARDNER PHYLLIS · CIK 0001238646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 F1 · shares: Represents an annual restricted stock award (the "RSA") granted pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the "Compensation Policy"). The shares underlying the RSA shall vest on May 14, 2021, the one year anniversary from the grant date, subject to Dr. Gardner's Continuous Service (as defined the Issuer's 2014 Equity Incentive Plan (the "Plan")) through such vesting date. Read SEC document |
| May 09, 2019 Filed May 10, 2019 21:05 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantStock Option (Right to buy) · Derivative | 9,000 | $0.00 Strike: $12.82 | $0.00 |
DisclosureSEC source: 0001479290-19-000058 · wf-form4_155753668980016.xml · derivative · entry 2 GARDNER PHYLLIS · CIK 0001238646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2029-05-08 F2 · derivative.exercise_date: The shares subject to the stock option shall vest on the one year anniversary, May 9, 2020, subject to Dr. Gardner's Continuous Service (as defined in the Plan) through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy. Read SEC document |
| May 09, 2019 Filed May 10, 2019 21:05 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantCommon Stock | 4,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001479290-19-000058 · wf-form4_155753668980016.xml · nonDerivative · entry 1 GARDNER PHYLLIS · CIK 0001238646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 F1 · shares: Represents an annual restricted stock award (the "RSA") granted pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the "Compensation Policy"). The shares underlying the RSA shall vest on the one year anniversary, May 9, 2020, subject to Dr. Gardner's Continuous Service (as defined the Issuer's 2014 Equity Incentive Plan (the "Plan")) through such vesting date. Read SEC document |
| February 08, 2019 Filed Feb 12, 2019 11:49 UTC | CohBar, Inc. CWBR · Entity 124935 | GrantStock Options (right to buy) · Derivative | 200,000 | $0.00 Strike: $3.15 | $0.00 |
DisclosureSEC source: 0001209191-19-009183 · doc4.xml · derivative · entry 1 GARDNER PHYLLIS · CIK 0001238646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2029-02-08 F1 · derivative.exercise_date: Shares subject to option shall vest in 48 successive monthly installments beginning February 8, 2019. Read SEC document |
| November 27, 2018 Filed Nov 28, 2018 19:52 UTC | Corium International, Inc. CORI · Entity 162158 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 15,000 | $12.50 Strike: $11.59 | $187,500.00 |
DisclosureSEC source: 0001567619-18-007065 · doc1.xml · derivative · entry 6 GARDNER PHYLLIS · CIK 0001238646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2027-11-30 F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR"). F2 · price: Pursuant to the Merger Agreement, at the effective time of the Merger, each option to purchase Shares that was vested and outstanding was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (x) the number of vested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option, plus (ii) one CVR for each Share issuable under such option. This option is fully vested. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the effective time of the Merger, each option to purchase Shares that was vested and outstanding was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (x) the number of vested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option, plus (ii) one CVR for each Share issuable under such option. This option is fully vested. Read SEC document |
| November 27, 2018 Filed Nov 28, 2018 19:52 UTC | Corium International, Inc. CORI · Entity 162158 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 15,000 | $12.50 Strike: $4.59 | $187,500.00 |
DisclosureSEC source: 0001567619-18-007065 · doc1.xml · derivative · entry 5 GARDNER PHYLLIS · CIK 0001238646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2026-12-21 F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR"). F2 · price: Pursuant to the Merger Agreement, at the effective time of the Merger, each option to purchase Shares that was vested and outstanding was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (x) the number of vested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option, plus (ii) one CVR for each Share issuable under such option. This option is fully vested. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the effective time of the Merger, each option to purchase Shares that was vested and outstanding was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (x) the number of vested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option, plus (ii) one CVR for each Share issuable under such option. This option is fully vested. Read SEC document |
| November 27, 2018 Filed Nov 28, 2018 19:52 UTC | Corium International, Inc. CORI · Entity 162158 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 12,000 | $12.50 Strike: $7.19 | $150,000.00 |
DisclosureSEC source: 0001567619-18-007065 · doc1.xml · derivative · entry 4 GARDNER PHYLLIS · CIK 0001238646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2025-12-17 F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR"). F2 · price: Pursuant to the Merger Agreement, at the effective time of the Merger, each option to purchase Shares that was vested and outstanding was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (x) the number of vested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option, plus (ii) one CVR for each Share issuable under such option. This option is fully vested. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the effective time of the Merger, each option to purchase Shares that was vested and outstanding was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (x) the number of vested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option, plus (ii) one CVR for each Share issuable under such option. This option is fully vested. Read SEC document |
| November 27, 2018 Filed Nov 28, 2018 19:52 UTC | Corium International, Inc. CORI · Entity 162158 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 12,000 | $12.50 Strike: $5.79 | $150,000.00 |
DisclosureSEC source: 0001567619-18-007065 · doc1.xml · derivative · entry 3 GARDNER PHYLLIS · CIK 0001238646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2024-12-03 F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR"). F2 · price: Pursuant to the Merger Agreement, at the effective time of the Merger, each option to purchase Shares that was vested and outstanding was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (x) the number of vested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option, plus (ii) one CVR for each Share issuable under such option. This option is fully vested. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the effective time of the Merger, each option to purchase Shares that was vested and outstanding was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (x) the number of vested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option, plus (ii) one CVR for each Share issuable under such option. This option is fully vested. Read SEC document |
| November 27, 2018 Filed Nov 28, 2018 19:52 UTC | Corium International, Inc. CORI · Entity 162158 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 7,920 | $12.50 Strike: $4.14 | $99,000.00 |
DisclosureSEC source: 0001567619-18-007065 · doc1.xml · derivative · entry 2 GARDNER PHYLLIS · CIK 0001238646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,920 shares Expires 2024-01-25 F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR"). F2 · price: Pursuant to the Merger Agreement, at the effective time of the Merger, each option to purchase Shares that was vested and outstanding was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (x) the number of vested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option, plus (ii) one CVR for each Share issuable under such option. This option is fully vested. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the effective time of the Merger, each option to purchase Shares that was vested and outstanding was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (x) the number of vested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option, plus (ii) one CVR for each Share issuable under such option. This option is fully vested. Read SEC document |
| November 27, 2018 Filed Nov 28, 2018 19:52 UTC | Corium International, Inc. CORI · Entity 162158 | Disposition to issuerCommon Stock | 34,203 | $12.50 | $427,537.50 |
DisclosureSEC source: 0001567619-18-007065 · doc1.xml · nonDerivative · entry 1 GARDNER PHYLLIS · CIK 0001238646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR"). F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR"). Read SEC document |
| May 10, 2018 Filed May 11, 2018 20:28 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantStock Option (Right to buy) · Derivative | 6,000 | $0.00 Strike: $29.15 | $0.00 |
DisclosureSEC source: 0001479290-18-000079 · wf-form4_152608489454453.xml · derivative · entry 2 GARDNER PHYLLIS · CIK 0001238646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2028-05-09 F2 · derivative.exercise_date: The shares subject to the stock option shall vest on the one year anniversary, May 10, 2019, subject to Dr. Gardner's Continuous Service (as defined in the Plan) through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy. Read SEC document |
| May 10, 2018 Filed May 11, 2018 20:28 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001479290-18-000079 · wf-form4_152608489454453.xml · nonDerivative · entry 1 GARDNER PHYLLIS · CIK 0001238646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 F1 · shares: Represents an annual restricted stock award (the "RSA") granted pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the "Compensation Policy"). The shares underlying the RSA shall vest on the one year anniversary, May 10, 2019, subject to Dr. Gardner's Continuous Service (as defined the Issuer's 2014 Equity Incentive Plan (the "Plan")) through such vesting date. Read SEC document |
| March 16, 2018 Filed Mar 16, 2018 20:35 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | Exercise / conversionCommon Stock · Derivative | 1,333 | $0.00 Strike: $2.55 | $0.00 |
DisclosureSEC source: 0001479290-18-000054 · wf-form4_152124692840531.xml · derivative · entry 5 GARDNER PHYLLIS · CIK 0001238646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,333 shares Expires 2020-07-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The Option is fully vested as of January 1, 2014. Read SEC document |
| March 16, 2018 Filed Mar 16, 2018 20:35 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | Exercise / conversionCommon Stock · Derivative | 4,000 | $0.00 Strike: $2.55 | $0.00 |
DisclosureSEC source: 0001479290-18-000054 · wf-form4_152124692840531.xml · derivative · entry 4 GARDNER PHYLLIS · CIK 0001238646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires 2018-04-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is fully vested as of January 1, 2012. Read SEC document |
| March 16, 2018 Filed Mar 16, 2018 20:35 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | SaleCommon Stock | 5,333 | $31.51 | $168,045.50 |
DisclosureSEC source: 0001479290-18-000054 · wf-form4_152124692840531.xml · nonDerivative · entry 3 GARDNER PHYLLIS · CIK 0001238646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 F1 · price: The price reported in Table 1, Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.50 to $31.55. Dr. Gardner undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 16, 2018 Filed Mar 16, 2018 20:35 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | Exercise / conversionCommon Stock | 1,333 | $2.55 | $3,399.15 |
DisclosureSEC source: 0001479290-18-000054 · wf-form4_152124692840531.xml · nonDerivative · entry 2 GARDNER PHYLLIS · CIK 0001238646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 16, 2018 Filed Mar 16, 2018 20:35 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | Exercise / conversionCommon Stock | 4,000 | $2.55 | $10,200.00 |
DisclosureSEC source: 0001479290-18-000054 · wf-form4_152124692840531.xml · nonDerivative · entry 1 GARDNER PHYLLIS · CIK 0001238646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 19:37 UTC | Corium International, Inc. CORI · Entity 162158 | GrantDirector Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $11.59 | $0.00 |
DisclosureSEC source: 0001140361-17-045105 · doc1.xml · derivative · entry 1 GARDNER PHYLLIS · CIK 0001238646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-11-30 F1 · derivative.exercise_date: The option vests as to 1/12th of the total number of shares on January 1, 2018 and then 1/12th monthly thereafter. Read SEC document |
| August 21, 2017 Filed Aug 21, 2017 18:07 UTC | Corium International, Inc. CORI · Entity 162158 | Exercise / conversionDirector Stock Option (Right to Buy) · Derivative | 33,064 | $0.00 Strike: $2.12 | $0.00 |
DisclosureSEC source: 0001140361-17-032873 · doc1.xml · derivative · entry 2 GARDNER PHYLLIS · CIK 0001238646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,064 shares Expires 2017-11-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option is fully vested. Read SEC document |
| August 21, 2017 Filed Aug 21, 2017 18:07 UTC | Corium International, Inc. CORI · Entity 162158 | Exercise / conversionCommon Stock | 33,064 | $2.12 | $70,128.74 |
DisclosureSEC source: 0001140361-17-032873 · doc1.xml · nonDerivative · entry 1 GARDNER PHYLLIS · CIK 0001238646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,203 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 11, 2017 Filed May 12, 2017 19:49 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $20.90 | $0.00 |
DisclosureSEC source: 0001209191-17-032208 · doc4.xml · derivative · entry 2 GARDNER PHYLLIS · CIK 0001238646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2027-05-10 F2 · derivative.exercise_date: The shares subject to the stock option shall vest on the one year anniversary, May 11, 2018, subject to Dr. Gardner's Continuous Service (as defined in the Plan) through such vesting date. The stock option represents an annual option grant pursuant to the Compensation Policy. Read SEC document |
| May 11, 2017 Filed May 12, 2017 19:49 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-032208 · doc4.xml · nonDerivative · entry 1 GARDNER PHYLLIS · CIK 0001238646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 F1 · shares: Represents an annual restricted stock award (the "RSA") granted pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the "Compensation Policy"). The shares underlying the RSA shall vest on the one year anniversary, May 11, 2018, subject to Dr. Gardner's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan (the "Plan")) through such vesting date. Read SEC document |
| December 22, 2016 Filed Dec 27, 2016 18:39 UTC | Corium International, Inc. CORI · Entity 162158 | GrantDirector Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $4.59 | $0.00 |
DisclosureSEC source: 0001140361-16-090847 · doc1.xml · derivative · entry 1 GARDNER PHYLLIS · CIK 0001238646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2026-12-21 F1 · derivative.exercise_date: The option vests as to 1/12th of the total number of shares on January 22, 2017 and then 1/12th monthly thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.